Lenalidomide

[SDL] Lenalidomide Capsule 5 mg, 10 mg, 15 mg, 25 mg

[MSHL] Lenalidomide Capsule 5 mg, 10 mg, 15 mg, 25 mg

For cancer treatment.

13/09/2024 Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions

The Ministry of Health’s Drug Advisory Committee has reviewed all available treatments for cancer to update the MOH List of Subsidised Drugs in line with local clinical practice and medical advancements. As part of this review, Technology Guidances have been prepared which describe the subsidy recommendations for many cancer drugs for specific clinical conditions. The remaining treatments which have been considered by the Committee are included in this document.

[R] Based on the available evidence, the Ministry of Health’s Drug Advisory Committee has recommended:

• Abemaciclib 50 mg, 100 mg and 150 mg tablets;

• Abiraterone acetate 250 mg tablets;

• Afatinib 20 mg, 30 mg and 40 mg tablets;

• Alectinib 150 mg capsule;

• Anagrelide 0.5 mg capsule;

• Atezolizumab 840 mg/14 mL and 1200 mg/20 mL concentrate for solution for infusion;

• Avelumab 200 mg/10 mL concentrate for solution for infusion;

• Axitinib 1 mg and 5 mg tablets;

• Azacitidine 100 mg injection;

• Bendamustine 25 mg and 100 mg concentrate for infusion;

• Bicalutamide 50 mg tablet;

• Bortezomib 3.5 mg injection;

• Brentuximab vedotin 50 mg powder for concentrate for solution for infusion;

• Brigatinib 30 mg, 90 mg and 180 mg tablets;

• Cabozantinib 20 mg, 40 mg and 60 mg tablets;

• Ceritinib 150 mg capsule;

• Cetuximab 100 mg/20 mL solution for infusion;

• Cisplatin 100 mg/100 mL concentrate for infusion;

• Cyproterone 50 mg tablet;

• Dabrafenib 50 mg and 75 mg capsules;

• Dasatinib 20 mg, 50 mg and 70 mg tablets;

• Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion;

• Epirubicin 50 mg/25 mL injection;

• Eribulin mesylate 1 mg/2 mL solution for injection;

• Erlotinib 100 mg and 150 mg tablets;

• Exemestane 25 mg tablet;

• Fludarabine phosphate 50 mg injection;

• Fulvestrant 250 mg/5 mL solution for injection;

• Gefitinib 250 mg tablet;

• Gilteritinib fumarate 40 mg tablet;

• Goserelin 3.6 mg and 10.8 mg depot injections;

• Imatinib 100 mg and 400 mg tablets;

• Ipilimumab 50 mg/10 mL concentrate for solution for infusion;

• Lapatinib 250 mg tablets;

• Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules;

• Leuprorelin acetate 3.75 mg and 11.25 mg depot injection;

• Lorlatinib 25 mg and 100 mg tablets;

• Megestrol 40 mg and 160 mg capsules;

• Midostaurin 25 mg capsule;

• Nilotinib 50 mg, 150 mg and 200 mg capsules;

• Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion;

• Obinutuzumab 1000 mg/40 mL concentrate for solution for infusion;

• Olaparib 100 mg and 150 mg tablets;

• Oxaliplatin 200 mg/40 mL concentrate for infusion;

• Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension;

• Palbociclib 75 mg, 100 mg and 125 mg capsules/tablets;

• Pazopanib 200 mg and 400 mg tablets;

• Pegylated liposomal doxorubicin 20 mg concentrate for infusion;

• Pembrolizumab 100 mg/4 mL solution for infusion;

• Pemetrexed 100 mg and 500 mg injections;

• Ponatinib 15 mg tablet;

• Ribociclib 200 mg tablet;

• Ruxolitinib 5 mg, 15 mg and 20 mg tablets;

• Somatropin 5 mg/1.5 mL and 10 mg/1.5 mL prefilled pens and solution for injection;

• Somatropin 4 mg and 5.3 mg/mL powder and solvent for solution for injection;

• Somatropin 5.83 mg/mL and 8 mg/mL solution for injection;

• Sunitinib 12.5 mg capsules;

• Trametinib 0.5 mg and 2 mg tablets; and

• Vinorelbine 50 mg/5 mL injection

for inclusion on the MOH Standard Drug List (SDL) or Medication Assistance Fund (MAF) in line with their registered indications or specific clinical criteria for treating cancer, in view of clinical need, and acceptable clinical and cost effectiveness.

[NR] Drugs that have not been recommended for subsidy are listed in the Annex.

For all drugs, the clinical indications, subsidy class, subsidy implementation dates (if applicable), and MediShield Life claim limits are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

DHCPL 25/08/2011 The association of Revlimid® (lenalidomide) with venous and arterial thromboembolic events

PEM 02/01/2025 Lenalidomide Grindeks: Healthcare Professional Educational Material - Pregnancy Prevention Programme

PEM 30/09/2024 LENLI Healthcare Professional Information Pack

PEM 26/03/2024 HEALTHCARE PROFESSIONALS BROCHURE FOR IMMUNOMODULATORY AGENTS: Revlimid® (Lenalidomide) and Pomalyst® (Pomalidomide)

PEM 19/02/2024 Manual for Healthcare Professionals PREGNANCY PREVENTION PROGRAM (PPP): MYOLID® (LENALIDOMIDE)

PEM 18/04/2023 LINADEX PHYSICIAN EDUCATIONAL MATERIAL (PEM)

PEM 14/04/2022 HEALTHCARE PROFESSIONAL INFORMATION PACK Lenalidomide-Teva (Lenalidomide): PPP- Pregnancy Prevention Program

PEM 24/08/2021 Reddy-Lenalidomide RMP Program: Prescriber & Pharmacy Guide

PMG 02/01/2025 Lenalidomide Grindeks: Patient Medication Guide

PMG 30/09/2024 LENLI Patient Brochure

PMG 26/03/2024 PATIENT MEDICATION GUIDE FOR IMMUNOMODULATORY AGENTS: Revlimid® (Lenalidomide) and Pomalyst® (Pomalidomide)

PMG 19/02/2024 Patient Manual PREGNANCY PREVENTION PROGRAM (PPP): MYOLID® (LENALIDOMIDE)

PMG 18/04/2023 LINADEX PREGNANCY PREVENTION PROGRAMME PATIENT MEDICATION GUIDE (PMG)

PMG 14/04/2022 Patient Brochure Lenalidomide-Teva (Lenalidomide): PPP- Pregnancy Prevention Program

PMG 24/08/2021 Reddy-Lenalidomide RMP Program: Patient Guide

Educational materials for healthcare professionals

Educational materials highlight specific safety concerns associated with the use of selected therapeutic products and provide advice on the actions required to optimize safe and effective use of these products.

Only educational materials approved by the Health Sciences Authority of Singapore (HSA) are listed. These materials are published with the agreement of the company responsible for producing them and are not intended to replace medical advice offered by healthcare professionals (HCP). As this website is updated monthly, please refer to HSA website for the most updated information.

Dear Healthcare Professional Letters (DHCPLs)

Dear Healthcare Professional Letters (DHCPL) are letters issued by a manufacturer or the HSA to healthcare professionals to communicate new or emerging safety, efficacy or quality information associated with the use of specific marketed therapeutic products.  As this website is updated monthly, please refer to HSA website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration